Literature DB >> 15015622

Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability.

Athanassios Dellas1, Alex Puhl, Peter Schraml, Sabine E Thomke, Josef Rüschoff, Michael J Mihatsch, Holger Moch.   

Abstract

BACKGROUND: Microsatellite instability (MSI) occurs in sporadic ovarian carcinomas. This study tests the hypothesis that ovarian carcinomas arising through the mutator pathway have distinctive clinical and molecular features that affect clinical outcome.
MATERIALS AND METHODS: The MSI status was evaluated in 66 ovarian carcinomas and 11 epithelial ovarian tumors of low malignant potential. For the analysis with the microsatellite markers, a fluorescence-based PCR method was employed and the prognostic significance of the MSI status was assessed. DNA copy number changes in tumors with and without MSI were analyzed by comparative genomic hybridization.
RESULTS: High-frequency MSI (MSI-H) was found in 30% of the carcinomas, whereas low-frequency MSI (MSI-L) occurred in 32%. In LMP tumors, only MSI-L was detected (18%). There was a trend for tumors with MSI-H and MSI-L to have a poor prognosis, but this relationship did not reach significance (p=0.09 and p=0.07, respectively). MSI-H in carcinomas was significantly associated with poor differentiation (p=0.03) and higher clinical stage (p=0.03). No correlation was found between different histological types of ovarian carcinoma and the microsatellite status. In a multivariate analysis, MSI at the dinucleotide repeat D5S346 was found to be of independent prognostic significance (p<0.008) for disease-specific survival. There was no association between the total number of genetic aberrations per tumor and the MSI status.
CONCLUSION: Microsatellite instability is a relatively common event in ovarian carcinoma. The data indicate that instability of a single microsatellite marker on chromosome 5 (D5S346) might be indicative of disease progression when detected in early clinical stages.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015622

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America.

Authors:  Megan A Murphy; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2011-04-04       Impact factor: 7.396

2.  Risk factors for ovarian cancers with and without microsatellite instability.

Authors:  Yakir Segev; Tuya Pal; Barry Rosen; John R McLaughlin; Thomas A Sellers; Harvey A Risch; Shiyu Zhang; Sun Ping; Steven A Narod; Joellen Schildkraut
Journal:  Int J Gynecol Cancer       Date:  2013-07       Impact factor: 3.437

Review 3.  Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.

Authors:  Tuya Pal; Jenny Permuth-Wey; Ambuj Kumar; Thomas A Sellers
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 4.  A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Thomas A Sellers
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

Review 5.  The molecular background of mucinous carcinoma beyond MUC2.

Authors:  Niek Hugen; Michiel Simons; Altuna Halilović; Rachel S van der Post; Anna J Bogers; Monica Aj Marijnissen-van Zanten; Johannes Hw de Wilt; Iris D Nagtegaal
Journal:  J Pathol Clin Res       Date:  2014-11-05

6.  Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.

Authors:  Simone Brandt; Eleftherios P Samartzis; Anne-Katrin Zimmermann; Daniel Fink; Holger Moch; Aurelia Noske; Konstantin J Dedes
Journal:  BMC Cancer       Date:  2017-01-10       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.